

# Steven C Wallis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3541216/publications.pdf>

Version: 2024-02-01

138  
papers

5,519  
citations

94433

37  
h-index

88630

70  
g-index

139  
all docs

139  
docs citations

139  
times ranked

4064  
citing authors

#	ARTICLE	IF	CITATIONS
1	DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current $\beta$ -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?. <i>Clinical Infectious Diseases</i> , 2014, 58, 1072-1083.	5.8	843
2	Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. <i>Intensive Care Medicine</i> , 2016, 42, 1535-1545.	8.2	244
3	Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. <i>Critical Care</i> , 2012, 16, R194.	5.8	233
4	Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study. <i>Critical Care</i> , 2015, 19, 164.	5.8	181
5	Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 2039-2043.	2.3	172
6	Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?. <i>Critical Care</i> , 2013, 17, R84.	5.8	166
7	Risk factors for target non-attainment during empirical treatment with $\beta$ -lactam antibiotics in critically ill patients. <i>Intensive Care Medicine</i> , 2014, 40, 1340-1351.	8.2	147
8	Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 196-207.	3.0	129
9	Low Plasma Cefepime Levels in Critically Ill Septic Patients: Pharmacokinetic Modeling Indicates Improved Troughs with Revised Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 2559-2561.	3.2	115
10	Copper(II) complexes of the fluoroquinolone antimicrobial ciprofloxacin. Synthesis, X-ray structural characterization, and potentiometric study. <i>Journal of Inorganic Biochemistry</i> , 1996, 62, 1-16.	3.5	112
11	Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?. <i>Critical Care</i> , 2015, 19, 28.	5.8	111
12	Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study. <i>Critical Care</i> , 2015, 19, 33.	5.8	108
13	Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1771-1778.	3.0	102
14	Assays for therapeutic drug monitoring of $\beta$ -lactam antibiotics: A structured review. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 367-375.	2.5	95
15	ASAP ECMO: Antibiotic, Sedative and Analgesic Pharmacokinetics during Extracorporeal Membrane Oxygenation: a multi-centre study to optimise drug therapy during ECMO. <i>BMC Anesthesiology</i> , 2012, 12, 29.	1.8	90
16	The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study. <i>Critical Care</i> , 2014, 18, 565.	5.8	87
17	Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. <i>Critical Care</i> , 2014, 18, R99.	5.8	87
18	The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically Ill Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study. <i>Clinical Infectious Diseases</i> , 2021, 72, 1369-1378.	5.8	85

#	ARTICLE	IF	CITATIONS
19	Cefepime Versus Cefpirome: The Importance of Creatinine Clearance. <i>Anesthesia and Analgesia</i> , 2003, 97, 1149-1154.	2.2	81
20	Co-administration of sub-antinociceptive doses of oxycodone and morphine produces marked antinociceptive synergy with reduced CNS side-effects in rats. <i>Pain</i> , 2000, 84, 421-428.	4.2	75
21	Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing. <i>Intensive Care Medicine</i> , 2001, 27, 363-370.	8.2	69
22	Plasma and Tissue Pharmacokinetics of Cefazolin in Patients Undergoing Elective and Semielective Abdominal Aortic Aneurysm Open Repair Surgery. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5238-5242.	3.2	68
23	Meropenem Dosing in Critically Ill Patients with Sepsis Receiving High-Volume Continuous Venovenous Hemofiltration. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2974-2978.	3.2	67
24	Can physicochemical properties of antimicrobials be used to predict their pharmacokinetics during extracorporeal membrane oxygenation? Illustrative data from ovine models. <i>Critical Care</i> , 2015, 19, 437.	5.8	67
25	Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds. <i>Critical Care</i> , 2014, 18, 657.	5.8	64
26	Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1495-1502.	3.0	60
27	Population Pharmacokinetics of Fosfomycin in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6471-6476.	3.2	59
28	Interaction of Norfloxacin with Divalent and Trivalent Pharmaceutical Cations. In Vitro Complexation and in Vivo Pharmacokinetic Studies in the Dog. <i>Journal of Pharmaceutical Sciences</i> , 1996, 85, 803-809.	3.3	56
29	Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	54
30	Cerebrospinal Fluid Penetration of High Doses of Intravenous Ciprofloxacin in Meningitis. <i>Clinical Infectious Diseases</i> , 2000, 31, 1131-1133.	5.8	51
31	Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 41-45.	2.5	50
32	Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration. <i>Intensive Care Medicine</i> , 2001, 27, 665-672.	8.2	47
33	DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic. <i>BMC Infectious Diseases</i> , 2012, 12, 152.	2.9	47
34	Synthesis and X-ray structural characterization of an iron(III) complex of the fluoroquinolone antimicrobial ciprofloxacin, [Fe(CIP)(NTA)]3 $\cdot$ 5H <sub>2</sub> O (NTA $\hat{=}$ Nitilotriacetato). <i>Polyhedron</i> , 1995, 14, 2835-2840.	2.2	45
35	Quantitative bioanalytical validation of fosfomycin in human whole blood with volumetric absorptive microsampling. <i>Bioanalysis</i> , 2015, 7, 2585-2595.	1.5	45
36	Altered antibiotic pharmacokinetics during extracorporeal membrane oxygenation: cause for concern?. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 726-727.	3.0	42

#	ARTICLE	IF	CITATIONS
37	Maximally effective dosing regimens of meropenem in patients with septic shock. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 191-198.	3.0	40
38	Effect of Obesity on the Population Pharmacokinetics of Meropenem in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4577-4584.	3.2	38
39	Effect of Obesity on the Population Pharmacokinetics of Fluconazole in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6550-6557.	3.2	38
40	Effect of different renal function on antibacterial effects of piperacillin against <i>Pseudomonas aeruginosa</i> evaluated via the hollow-fibre infection model and mechanism-based modelling. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2509-2520.	3.0	38
41	Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	35
42	Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	34
43	Caspofungin Population Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1057-1068.	3.5	32
44	Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 542-546.	2.5	30
45	Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2508-2516.	3.0	29
46	Effect of time on recovery of plasma microsamples for the quantitative determination of vancomycin. <i>Bioanalysis</i> , 2016, 8, 2235-2242.	1.5	29
47	Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4901-4909.	3.2	29
48	Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 39-44.	2.5	28
49	A simple LC-MS/MS method using HILIC chromatography for the determination of fosfomycin in plasma and urine: Application to a pilot pharmacokinetic study in humans. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 105, 39-45.	2.8	28
50	<i>Ex Vivo</i> Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	27
51	Rapid and economical high-performance liquid chromatographic method for the determination of norfloxacin in serum using a microparticulate C18 guard cartridge. <i>Biomedical Applications</i> , 1995, 674, 306-309.	1.7	25
52	Clinical application of microsampling versus conventional sampling techniques in the quantitative bioanalysis of antibiotics: a systematic review. <i>Bioanalysis</i> , 2018, 10, 407-423.	1.5	25
53	Pharmacokinetics of meropenem and piperacillin in critically ill patients with indwelling surgical drains. <i>International Journal of Antimicrobial Agents</i> , 2013, 42, 90-93.	2.5	24
54	A validated method for the quantification of fosfomycin on dried plasma spots by HPLC-MS/MS: Application to a pilot pharmacokinetic study in humans. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 115, 509-514.	2.8	23

#	ARTICLE	IF	CITATIONS
55	A UHPLC-MS/MS method for the simultaneous determination of piperacillin and tazobactam in plasma (total and unbound), urine and renal replacement therapy effluent. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 148, 324-333.	2.8	23
56	Spectroscopic and ligand-field analysis of the spin-orbit interaction between the $1E_g$ and $3T_2g$ states in bis(1,4,7-triazacyclononane)nickel(II). <i>Journal of the Chemical Society Dalton Transactions</i> , 1992, , 2971-2976.	1.1	22
57	Total and unbound ceftriaxone pharmacokinetics in critically ill Australian Indigenous patients with severe sepsis. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 748-752.	2.5	22
58	Determination of Cefalothin and Cefazolin in Human Plasma, Urine and Peritoneal Dialysate by UHPLC-MS/MS: application to a pilot pharmacokinetic study in humans. <i>Biomedical Chromatography</i> , 2016, 30, 872-879.	1.7	22
59	Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients. <i>Critical Care</i> , 2019, 23, 205.	5.8	22
60	Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy?. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 528-533.	3.0	21
61	Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against <i>Pseudomonas aeruginosa</i> for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	21
62	Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	3.2	21
63	A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	3.2	21
64	Is there a role for microsampling in antibiotic pharmacokinetic studies?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 601-614.	3.3	20
65	Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 227-231.	2.5	20
66	Pharmacokinetics of a novel dosing regimen of oral melatonin in critically ill patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 467-72.	2.3	19
67	Development of simulated and ovine models of extracorporeal life support to improve understanding of circuit-host interactions. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2012, 14, 105-11.	0.1	19
68	Pharmacokinetics of Intraperitoneal Gentamicin in Peritoneal Dialysis Patients with Peritonitis (GIPD) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	4.9	18
69	Defining optimal dosing of ciprofloxacin in patients with septic shock. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1662-1669.	3.0	18
70	An LC-MS/MS method to determine vancomycin in plasma (total and unbound), urine and renal replacement therapy effluent. <i>Bioanalysis</i> , 2017, 9, 911-924.	1.5	17
71	Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	17
72	Lung Pharmacokinetics of Tobramycin by Intravenous and Nebulized Dosing in a Mechanically Ventilated Healthy Ovine Model. <i>Anesthesiology</i> , 2019, 131, 344-355.	2.5	17

#	ARTICLE	IF	CITATIONS
73	Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1643-1650.	3.0	16
74	Population Pharmacokinetics of Levetiracetam in Patients with Traumatic Brain Injury and Subarachnoid Hemorrhage Exhibiting Augmented Renal Clearance. <i>Clinical Pharmacokinetics</i> , 2021, 60, 655-664.	3.5	16
75	Evaluation of Meropenem+Ciprofloxacin Combination Dosage Regimens for the Pharmacokinetics of Critically Ill Patients With Augmented Renal Clearance. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1104-1115.	4.7	16
76	Cerebrospinal Fluid Penetration of Ceftolozane-Tazobactam in Critically Ill Patients with an Indwelling External Ventricular Drain. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	3.2	15
77	Ceftolozane+tazobactam in an elastomeric infusion device for ambulatory care: an in vitro stability study. <i>European Journal of Hospital Pharmacy</i> , 2020, 27, e84-e86.	1.1	15
78	Pharmacokinetics of Piperacillin in Critically Ill Australian Indigenous Patients with Severe Sepsis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 7402-7406.	3.2	14
79	Sampling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patients. <i>BMC Infectious Diseases</i> , 2016, 16, 103.	2.9	14
80	Conventional Pig as Animal Model for Human Renal Drug Excretion Processes: Unravelling the Porcine Renal Function by Use of a Cocktail of Exogenous Markers. <i>Frontiers in Pharmacology</i> , 2020, 11, 883.	3.5	14
81	Prophylactic Cefazolin Dosing in Women With Body Mass Index $\geq 35 \text{ kg m}^{-2}$ Undergoing Cesarean Delivery: A Pharmacokinetic Study of Plasma and Interstitial Fluid. <i>Anesthesia and Analgesia</i> , 2020, 131, 199-207.	2.2	14
82	Can We Use an Ex Vivo Continuous Hemofiltration Model to Describe the Adsorption and Elimination of Meropenem and Piperacillin?. <i>International Journal of Artificial Organs</i> , 2015, 38, 419-424.	1.4	13
83	Intravascular administration sets are accurate and in appropriate condition after 7 days of continuous use: an in vitro study. <i>Journal of Advanced Nursing</i> , 2002, 37, 330-337.	3.3	12
84	Analysis of capillary microsamples obtained from a skin-prick to measure vancomycin concentrations as a valid alternative to conventional sampling: A bridging study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 169, 288-292.	2.8	12
85	Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model against <i>Klebsiella pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2633-2640.	3.0	12
86	Population pharmacokinetics of cefepime in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study). <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106466.	2.5	12
87	Stability of Antibiotics for Intraperitoneal Administration in Extraneal 7.5% Icodextrin Peritoneal Dialysis Bags (Stab Study). <i>Peritoneal Dialysis International</i> , 2016, 36, 421-426.	2.3	11
88	Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 206-214.	3.2	11
89	A validated LC-MSMS method for the simultaneous quantification of meropenem and vaborbactam in human plasma and renal replacement therapy effluent and its application to a pharmacokinetic study. <i>Analytical and Bioanalytical Chemistry</i> , 2019, 411, 7831-7840.	3.7	11
90	An Integrated Dialysis Pharmacometric (IDP) Model to Evaluate the Pharmacokinetics in Patients Undergoing Renal Replacement Therapy. <i>Pharmaceutical Research</i> , 2020, 37, 96.	3.5	10



#	ARTICLE	IF	CITATIONS
91	An UHPLC-MS/MS method for the simultaneous determination of ampicillin and sulbactam in human plasma and urine. <i>Bioanalysis</i> , 2015, 7, 2311-2319.	1.5	9
92	Evidence of clinical response and stability of Ceftolozane/Tazobactam used to treat a carbapenem-resistant <i>Pseudomonas Aeruginosa</i> lung abscess on an outpatient antimicrobial program. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 941-942.	2.5	9
93	Population Pharmacokinetics of Piperacillin and Tazobactam in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation: an ASAP ECMO Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0143821.	3.2	9
94	Accuracy of pleural fluid pH and PCO <sub>2</sub> measurement in a blood gas analyser. Analysis of bias and precision. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1999, 59, 619-626.	1.2	8
95	Population Pharmacokinetics and Dosing Simulations of Ceftriaxone in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (An ASAP ECMO Study). <i>Clinical Pharmacokinetics</i> , 2022, 61, 847-856.	3.5	8
96	Multicenter Population Pharmacokinetic Study of Unbound Ceftriaxone in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0218921.	3.2	8
97	Pharmacokinetics of Intraperitoneal Cefalothin and Cefazolin in Patients Being Treated for Peritoneal Dialysis-Associated Peritonitis. <i>Peritoneal Dialysis International</i> , 2016, 36, 415-420.	2.3	7
98	A research pathway for the study of the delivery and disposition of nebulised antibiotics: an incremental approach from in vitro to large animal models. <i>Intensive Care Medicine Experimental</i> , 2018, 6, 17.	1.9	7
99	A pharmacokinetic case study of intravenous posaconazole in a critically ill patient with hypoalbuminaemia receiving continuous venovenous haemodiafiltration. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 506-509.	2.5	7
100	In-vitro adsorption and sieving coefficient of ticarcillin-clavulanate during continuous haemofiltration. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 261-264.	2.5	7
101	Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against <i>Pseudomonas aeruginosa</i> in a Dynamic <i>In Vitro</i> Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	7
102	Clinically Relevant Epithelial Lining Fluid Concentrations of Meropenem with Ciprofloxacin Provide Synergistic Killing and Resistance Suppression of Hypermutable <i>Pseudomonas aeruginosa</i> in a Dynamic Biofilm Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	7
103	Population Pharmacokinetics of Vancomycin in Critically Ill Adult Patients Receiving Extracorporeal Membrane Oxygenation (an ASAP ECMO Study). <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0137721.	3.2	7
104	Evaluation of low-volume plasma sampling for the analysis of meropenem in clinical samples. <i>Analytical and Bioanalytical Chemistry</i> , 2022, 414, 2155-2162.	3.7	7
105	Recovery rates of combination antibiotic therapy using in vitro microdialysis simulating in vivo conditions. <i>Journal of Pharmaceutical Analysis</i> , 2018, 8, 407-412.	5.3	6
106	Population Pharmacokinetics of Periarticular Ketorolac in Adult Patients Undergoing Total Hip or Total Knee Replacement Surgery. <i>Anesthesia and Analgesia</i> , 2019, 129, 701-708.	2.2	6
107	Microsampling to support pharmacokinetic clinical studies in pediatrics. <i>Pediatric Research</i> , 2022, 91, 1557-1561.	2.3	6
108	Oral fosfomycin activity against <i>Klebsiella pneumoniae</i> in a dynamic bladder infection in vitro model. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1324-1333.	3.0	6

#	ARTICLE	IF	CITATIONS
109	The pharmacokinetics of meropenem and piperacillin-tazobactam during sustained low efficiency haemodiafiltration (SLED-HDF). <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 239-247.	1.9	5
110	Pharmacokinetics of fluconazole and ganciclovir as combination antimicrobial chemotherapy on ECMO: a case report. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106431.	2.5	5
111	Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Meropenem in Neurocritical Care Patients: a Prospective Two-Center Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	3.2	5
112	Characterisation of 40â€mg/ml and 100â€mg/ml tobramycin formulations for aerosol therapy with adult mechanical ventilation. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 50, 93-99.	2.6	4
113	Pharmacokinetics of Total and Unbound Cefazolin during Venous-Arterial Extracorporeal Membrane Oxygenation: A Case Report. <i>Chemotherapy</i> , 2019, 64, 115-118.	1.6	4
114	Ticarcillin and piperacillin adsorption on to polyethersulfone haemodiafilter membranes in an ex-vivo circuit. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106058.	2.5	4
115	Comparative Plasma Pharmacokinetics of Ceftriaxone and Ertapenem in Normoalbuminemia, Hypoalbuminemia, and Albumin Replacement in a Sheep Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	4
116	Prospective Cohort Study of Micafungin Population Pharmacokinetic Analysis in Plasma and Peritoneal Fluid in Septic Patients with Intra-abdominal Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0230720.	3.2	4
117	A validated LC-MS/MS method for the simultaneous quantification of the novel combination antibiotic, ceftolozaneâ€tazobactam, in plasma (total and unbound), CSF, urine and renal replacement therapy effluent: application to pilot pharmacokinetic studies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 921-933.	2.3	4
118	Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against <i>Pseudomonas aeruginosa</i> for the Pharmacokinetics of Critically Ill Patients in a Dynamic Infection Model. <i>Antibiotics</i> , 2022, 11, 101.	3.7	4
119	Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against <i>Pseudomonas aeruginosa</i> Bacteremia in the Hollow-Fiber Infection Model. <i>Microbiology Spectrum</i> , 2022, 10, e0052522.	3.0	4
120	Plasma and Interstitial Fluid Pharmacokinetics of Prophylactic Cefazolin in Elective Bariatric Surgery Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 0, , .	3.2	4
121	A Loading Micafungin Dose in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration or Continuous Venovenous Hemodiafiltration: A Population Pharmacokinetic Analysis. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 747-755.	2.0	3
122	Caspofungin Population Pharmacokinetic Analysis in Plasma and Peritoneal Fluid in Septic Patients with Intra-Abdominal Infections: A Prospective Cohort Study. <i>Clinical Pharmacokinetics</i> , 2022, 61, 673-686.	3.5	3
123	Population pharmacokinetics of ciprofloxacin in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study). <i>Anaesthesia, Critical Care &amp; Pain Medicine</i> , 2022, , 101080.	1.4	3
124	Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum Î²-lactamase-producing and non-producing <i>Escherichia coli</i> clinical isolates in a hollow-fibre infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2448-2455.	3.0	3
125	Propylene Glycol and Glycerol Concentration in Ultrasound Gel. <i>Regional Anesthesia and Pain Medicine</i> , 2013, 38, 75-76.	2.3	2
126	Reply to Rhodes et al. <i>Clinical Infectious Diseases</i> , 2014, 59, 907-908.	5.8	2



#	ARTICLE	IF	CITATIONS
127	Population pharmacokinetics of ticarcillin in critically ill patients receiving extended daily diafiltration. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 351-355.	2.5	2
128	Low levels of salicylic acid and salicyluric acid are present in synovial fluid of patients taking aspirin at the time of knee arthroplasty surgery. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2020, 47, 1635-1637.	1.9	2
129	Pharmacodynamic Evaluation of a Single Dose versus a 24-Hour Course of Multiple Doses of Cefazolin for Surgical Prophylaxis. <i>Antibiotics</i> , 2021, 10, 602.	3.7	2
130	Development and validation of a UHPLC-MS/MS method to measure cefotaxime and metabolite desacetylcefotaxime in blood plasma: a pilot study suitable for capillary microsampling in critically ill children. <i>Analytical and Bioanalytical Chemistry</i> , 2021, 413, 4483-4491.	3.7	2
131	Pharmacodynamics of once- versus twice-daily dosing of nebulized amikacin in an in vitro Hollow-Fiber Infection Model against 3 clinical isolates of <i>Pseudomonas aeruginosa</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 100, 115329.	1.8	2
132	<i>In vitro</i> effect of synovial fluid from patients undergoing arthroplasty surgery on MRSA biofilm formation. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1041-1044.	3.0	2
133	A validated UHPLC-MS/MS method for the measurement of riluzole in plasma and myocardial tissue samples. <i>Biomedical Chromatography</i> , 2017, 31, e4030.	1.7	1
134	Pharmacokinetics of Sulfamethoxazole and Trimethoprim During Venovenous Extracorporeal Membrane Oxygenation: A Case Report. <i>Pharmacotherapy</i> , 2020, 40, 713-717.	2.6	1
135	Innovation in microsampling for therapeutic drug monitoring of gentamicin in neonates: a proof-of-concept study. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106513.	2.5	1
136	Optimal dosing of cefotaxime and desacetylcefotaxime for critically ill paediatric patients. Can we use microsampling?. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2227-2237.	3.0	1
137	Pharmacodynamic evaluation of piperacillin/tazobactam against extended-spectrum $\beta$ -lactamase-producing versus non-producing <i>Escherichia coli</i> in a hollow-fibre infection model. <i>International Journal of Antimicrobial Agents</i> , 2022, , 106623.	2.5	1
138	Use of the Hollow-Fiber Infection Model to Measure the Effect of Combination Therapy of Septic Shock Exposures of Meropenem and Ciprofloxacin against Intermediate and Resistant <i>Pseudomonas aeruginosa</i> Clinical Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, , e0214021.	3.2	0